GlassScriptPhysician profile
Timothy M Spiegel
NPI 1700870243
$10,703.47
in general payments reported to CMS, 2019-2025
22 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,572 · 2020: $912 · 2021: $1,010 · 2022: $1,501 · 2023: $1,726 · 2024: $1,616 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,708.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,024.98 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,222.95 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,107.30 | 2019-2025 | |
| Glaxosmithkline, LLC. | $663.78 | 2021-2025 | Benlysta |
| Pfizer INC. | $564.43 | 2019-2025 | |
| Genzyme Corporation | $555.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $426.65 | 2021-2024 | Saphnelo |
| Lilly USA, LLC | $403.52 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $244.37 | 2023-2025 | Lupkynis |
| Janssen Biotech, INC. | $98.23 | 2019-2024 | Simponi Aria, Tremfya |
| Sanofi-Aventis U.S. LLC | $90.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.20 | 2021-2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $40.61 | 2019-2024 | Strensiq |
| Celgene Corporation | $37.23 | 2019 | |
| Ucb, INC. | $36.72 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.49 | 2019-2021 | |
| Pacira Therapeutics, INC. | $23.99 | 2019 | |
| Mylan Institutional INC. | $20.96 | 2023 | Hulio |
| Sobi, INC | $18.26 | 2024 | |
| Gilead Sciences, INC. | $18.22 | 2019 | |
| Almatica Pharma LLC | $16.84 | 2025 | Teriparatide |
| Mallinckrodt Enterprises LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Spiegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.